Crinetics Pharmaceuticals, Inc. (CRNX)
CRNX · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2015
Who owns Crinetics Pharmaceuticals, Inc.
As filed with the SECHolders of 5% or more
6
Farallon Capital Management, L.L.C. holds 8.5% of Common Stock, par value $0.001 per share (the "Shares"), as its SCHEDULE 13G/A filed Aug 3, 2026 says.
Directors and officers
13
report now, of 23 people on the record since 2018. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
Farallon Capital Management, L.L.C.
SCHEDULE 13G/A · filed Aug 3, 2026 · Common Stock, par value $0.001 per share (the "Shares")
Dapice Joshua J.
SCHEDULE 13G/A · filed Feb 5, 2026 · Common Stock, par value $0.001 per share (the "Shares") · 6% in Sep 8, 2025
Wellington Management Group LLP
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock · 7.8% in May 15, 2026
Driehaus Capital Management LLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock
Vanguard Capital Management
SCHEDULE 13G · filed Apr 29, 2026 · Common Stock
T. Rowe Price Associates, Inc.
SCHEDULE 13G/A · filed May 15, 2026 · COMMON STOCK
Fmr LLC
SCHEDULE 13G/A · filed Aug 7, 2026 · COMMON STOCK · reported falling below 5%, from 15% in May 12, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%, from 10% in Apr 7, 2025
What CRNX reports owning in othersstakes of 5% or more, and other ties
Crinetics Pharmaceuticals, Inc. reports no stake in another company in the record.
Insider tradesForm 4
19sales
0purchases
19sales on a scheduled plan
8people selling
$6.7Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window8 of 43 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Knight Jeff E. | Chief Dev. & Operating Officer | 3 | $3.8M | 3 | 0 | $0 |
| Struthers Richard Scott | President & CEO | 2 | $800,000 | 2 | 0 | $0 |
| Pizzuti Dana | Chief Med and Dev Officer | 4 | $600,000 | 4 | 0 | $0 |
| Betz Stephen F. | Chief Scientific Officer | 2 | $400,000 | 2 | 0 | $0 |
| Okey Stephanie | director | 3 | $400,000 | 3 | 0 | $0 |
| Schilke Tobin | Chief Financial & Infra. Ofcr. | 1 | $300,000 | 1 | 0 | $0 |
| Vivaldi Coelho Rogerio | director | 3 | $300,000 | 3 | 0 | $0 |
| Kalofonos Isabel | Chief Commercial Officer | 1 | $100,000 | 1 | 0 | $0 |